y*****l 发帖数: 5997 | 1 12/12. Have spt @ 1.75.
YM BioSciences to Report Updated Phase I/II Data for CYT387 at ASH 2011
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced it would
report updated results from its Phase I/II myelofibrosis study of CYT387, a
JAK1/JAK2 inhibitor, in a poster session to be held from 6:00pm - 8:00pm on
Monday, December 12th at the 53rd Annual Meeting of the American Society of
Hematology (ASH) being held in San Diego, California. The Company also
reported updated results today fr... 阅读全帖 |
|
A******d 发帖数: 571 | 2 问楼上几位,jak2-stat5b 作的成功吗?我用的phosphorylated jak2 or stat5b 都杂
带居多,正经带很弱,最后还出现奇怪的结果,stat5b被phosphorylated,但是jak2 没
有。 |
|
s***n 发帖数: 31 | 3 紧急求助:
今年四月初,我妈妈在长沙湘雅医院本想做胆囊结石的术前检查,结果查出血小板924
,是正常值的3倍。当即就在医院做了骨穿和白血病的筛查。
11天后,出了结果骨髓细胞学图文报告单的诊断意见是:骨髓增生活跃,粒系正常,红
系偏低。巨核细胞减少,血小板大堆分布。JAK2/G1846T(V617F)突变基因分型报告单的
结果是JAK2野生型
期间吃了半月双莫达密片,血小板为540。继续吃药半月后又为1004,后来又在湘雅医
院开了羟基脲片服用,以及重组人干扰素注射,同时继续服用双莫达密。目前已使用两
月,血小板皆在600上下,无法恢复正常值!这些药物副作用极大,每次注射后一天都
有些发热,体温偏高,还有就是头晕,乏力,四肢酸痛厉害。这些药物都是化疗辅助药
物,都是通过其药物副作用来降低血小板。一来,药物作用不理想,二来,副作用太大
!因此,我们想更换治疗方式。现在该如何治疗?真诚请教这里的各位!!全家都感谢
你们!!! |
|
s***n 发帖数: 31 | 4 紧急求助:
今年四月初,我妈妈在长沙湘雅医院本想做胆囊结石的术前检查,结果查出血小板924
,是正常值的3倍。当即就在医院做了骨穿和白血病的筛查。
11天后,出了结果骨髓细胞学图文报告单的诊断意见是:骨髓增生活跃,粒系正常,红
系偏低。巨核细胞减少,血小板大堆分布。JAK2/G1846T(V617F)突变基因分型报告单的
结果是JAK2野生型
期间吃了半月双莫达密片,血小板为540。继续吃药半月后又为1004,后来又在湘雅医
院开了羟基脲片服用,以及重组人干扰素注射,同时继续服用双莫达密。目前已使用两
月,血小板皆在600上下,无法恢复正常值!这些药物副作用极大,每次注射后一天都
有些发热,体温偏高,还有就是头晕,乏力,四肢酸痛厉害。这些药物都是化疗辅助药
物,都是通过其药物副作用来降低血小板。一来,药物作用不理想,二来,副作用太大
!因此,我们想更换治疗方式。现在该如何治疗?真诚请教这里的各位!!全家都感谢
你们!!! |
|
x*****h 发帖数: 314 | 5 Jak2阳性还叫什么非特异性的罗,本质就是恶性的,最后的发展几乎是骨髓纤维化(慢
慢骨髓衰竭),的确没有很好的办法,诺华近期应该会推出一种JAK2抑制剂,但说实话
,就如慢粒神药格列卫,可以延缓病程进展,但无法根治。 |
|
x*****h 发帖数: 314 | 6 Jak2阳性还叫什么非特异性的罗,本质就是恶性的,最后的发展几乎是骨髓纤维化(慢
慢骨髓衰竭),的确没有很好的办法,诺华近期应该会推出一种JAK2抑制剂,但说实话
,就如慢粒神药格列卫,可以延缓病程进展,但无法根治。 |
|
m*****y 发帖数: 17 | 7 3月2日,生命科学学院2011届本科毕业生宋卢挺作为并列第一作者,其研究论文发表于
国际顶级学术期刊《细胞》(2010年影响因子为32.401)上,并登上了该期研究新亮点。
据悉,宋卢挺是首批加入武汉大学-华大基因联合培养创新班的7名学生之一,于2010年
3月赴深圳华大基因研究院从事基因组学研究工作。联合培养期间,宋卢挺充分利用华
大基因研究院作为全球最大基因组学研究中心的平台优势,积极把握机会,在2010年第
五届国际基因组大会(ICG-V)上作主题报告,最终成长为华大基因研究院癌症单细胞
研究的负责人。
此次发表的论文题为《单细胞外显子测序和揭示一例JAK2突变阴性骨髓增生性肿瘤的单
克隆起源机制》(Single-Cell Exome Sequencing and Monoclonal Evolution of a
JAK2-Negative Myeloproliferative Neoplasm),在本项研究中,以宋卢挺为项目负
责人的研究团队研发了一种解析单细胞基因组的新方法,并将该方法应用于原发性血小
板增多症(ET,一种血癌)的肿瘤内部遗传特征研究,在肿瘤研究上获得突破性... 阅读全帖 |
|
B******y 发帖数: 2255 | 8 9/9新高后,缩量调整,TA走的不差,FA继续看好,9/17/2013, 看到一片分析的文章,
很多看法和我的估计一样,代替我自己码字了,转过来大家看看:
The long-term value of Incyte Corporation (NASDAQ:INCY) is undervalued by
the market, as the second half of 2013 could be catalyst-rich for the pharma
company.
Incyte's key product is Jakafi, a selective inhibitor of Janus kinases 1 and
2 (JAK1 and JAK2). Jakafi is indicated for treatment of patients with
intermediate or high-risk myelofibrosis (MF), including primary MF, post-
polycythemia vera MF and post-essential t... 阅读全帖 |
|
b*****h 发帖数: 783 | 9 只要它的jak2 inhibitor 在就没问题。jak2还在二期,是个长期投资。 |
|
b*****h 发帖数: 783 | 10 YMI 是个加拿大的biotech,它本来只有一个EGFR抗体药物-Nimotuzumab,做到后来都
濒临破产了。
后来公司合并了Cytopia, 获得了Cytopia JAK2 inhibitor--CYT387,不过那时CYT387
还在preclinical阶段. JAK inhibitor
目前主要在开发治疗Myeloproliferative Disorder,
(做JAK2 inhibitor 的领头公司是INCY,看看它过去股价的走势就知道大家对JAK
inhibitor的热情。)
YMI 的CYT387正在做phaseI/II的 clinical trial. 因为效果不错。trial的人数扩展
了好几次。
从interim data看,治疗效果和INCY的Ruxolitinib类似,但在对改善anemia的效果比
INCY 的Ruxolitinib还要有希望。
phase II 的fulll data在年底出来。 |
|
|
f**s 发帖数: 18 | 12 这个病大部分人进展很慢,以前有一部分病人用化疗药,就是你说的按白血病治疗,后
来发现10多年以后由于药物引起的白血病不少,总体来说弊多利少,所以现在治疗手段
有争论。麦地版那边提到的JAK2针对性的一期临床,我觉得还很不成熟,如果病情不重
,就用放血疗法挺好,没啥副作用。
当然需要血液科医生长期观察,如果病情进展或者有变化,随时调整治疗方案。 |
|
f******I 发帖数: 769 | 13
if that's regarding JAK2 mutation, from that new england journal article
this month, it's still fairly early in the research, |
|
W********r 发帖数: 158 | 14 I believe what you meant is Essential thromobytosis (ET). It can be
classified into different risk group, low and high. The goal is to prevent
thromboembolic event, using aspirin or hydroxyurea. About 50% patients with
ET have JAK2 mutation. A oral JAK inhibitor ruxolitinib was recently
approved by FDA to treat myelofibrosis (end stage of ET). Several clinical
study is on going to test the drug in ET before progressing to MF with
promising result. |
|
s****2 发帖数: 72 | 15 我妻子今年六月身体检查时被发现白细胞增多,最高时15.9 (normal 3.4-10.8), 现
在降到13.1. 骨髓检查的结论是非特异性骨髓增生性疾病 或hypercellular marrow
with involvement by a chronic myeloproliferative neoplasma. negative for 慢
性和急性白血病。jak2 is positive. 医生说没有特别的治疗办法。3个月后重新查白
血球。现在心里很不安,请问有没有这方面知道多的朋友,给我们一些建议。也希望你
们的祝福。 谢谢! |
|
s****2 发帖数: 72 | 16 我妻子今年六月身体检查时被发现白细胞增多,最高时15.9 (normal 3.4-10.8), 现
在降到13.1. 骨髓检查的结论是非特异性骨髓增生性疾病 或hypercellular marrow
with involvement by a chronic myeloproliferative neoplasma. negative for 慢
性和急性白血病。jak2 is positive. 医生说没有特别的治疗办法。3个月后重新查白
血球。现在心里很不安,请问有没有这方面知道多的朋友,给我们一些建议。也希望你
们的祝福。 谢谢! |
|
s****2 发帖数: 72 | 17 我妻子今年六月身体检查时被发现白细胞增多,最高时15.9 (normal 3.4-10.8), 现
在降到13.1. 骨髓检查的结论是非特异性骨髓增生性疾病 或hypercellular marrow
with involvement by a chronic myeloproliferative neoplasma. negative for 慢
性和急性白血病。jak2 is positive. 医生说没有特别的治疗办法。3个月后重新查白
血球。现在心里很不安,请问有没有这方面知道多的朋友,给我们一些建议。也希望你
们的祝福。 谢谢! |
|
A*e 发帖数: 202 | 18 大家好!这是姐姐同事的小孩,2岁多,红细胞和血红蛋白异常增多,在国内查了很多
医院,找不到病因,再拖下去有生命危险,因此请朋友来网上求救,大家如果有什么线
索可以提供,非常感谢!哎,可怜天下父母心啊,看重生命无助的感觉。。。
【病历发展情况如下】
2015.2.5出生,足月顺产。
2015.2.7 因“新生儿高胆红素血症”“头颅血肿(右侧)”住院(青岛市市立医院)
,予蓝光照射及口服药物治疗,于
2015.2.10基本痊愈出院。期间于
2015.2.8测血常规,红细胞计数5.93×1012/L,血红蛋白225g/L,红细胞压积63.50.
2015.2.9测血常规,红细胞计数5.74×1012/L,血红蛋白216g/L,红细胞压积60.90.
2015.8.14测血常规(青岛市市立医院),红细胞计数6.67×1012/L,血红蛋白172g/L,
红细胞压积54.60.当时问医生,回答说是没什么事,期间也没有发现什么异常,只是每
次哭闹的时候头部面部都变红。
2015.9.24测血常规(青岛市市立医院),红细胞计数7.03×1012/L,血红蛋白181g/L,
红细胞压积56.70
20... 阅读全帖 |
|
f*******1 发帖数: 1308 | 19 INCY还是相当猛的,有批了的药 JAK1/JAK2 inhibitors (Jakafi), 还有Iclusig (BCR
-ABL),另外在小分子抑制剂(JAK, PI3K, LSD1,FGFR, PIM,BRD...)和Immunotherapy(
IDO1, PD-1, ARG, OX40, GITR...)还有一堆很有意思的pipeline,针对各种肿
瘤的。 |
|
F******k 发帖数: 7375 | 20 Several review opportunities.
I don't have time to review but would like to recommend somebody who are
looking for such opportunities.
1.
Journal: Hematology
Key words: Arsenic trioxide; Acute promyelocytic leukemia; Nuclear factor
kappa β; Pin1; PinX1
2.
Journal: Experimental Hematology
Key words: JAK2 V617F; GATA-1; FOG-1; DNA methylation; Histone acetylation;
HP1a;
3.
Journal: Molecular and Cellular Biochemistry
Key words: cell-conditioned medium, cord blood stem cell, paracrine
mechanism,
se... 阅读全帖 |
|
s****t 发帖数: 17096 | 21 2013
以下白金:
Rayman Legends
PlayStation All-Stars Battle Royale
Soul Sacrifice
Okami
ワンピース 海賊無双2
海贼无双 1
Persona 4 Golden
Littlebigplanet Vita
Littlebigplanet 2
MotoGP13
ハローキティといっしょ!ブロッククラッシュV
初音ミク -Project DIVA- f
Farming Simulator
Sly Cooper 4
Rachet and Clank: Full Frontal Assault
Need for Speed Most wanted
Tearaway
Virtue's Last Reward
Madden NFL 13
FIFA 13
Virtua Tennis 4
Atelier Totori The Adventurer of Arland
F1 2011
Plants Vs. Zombies
Michael Jackson The Experience HD
Zombie Tycoon 2: Brain... 阅读全帖 |
|
x*****g 发帖数: 42 | 22 是这片吧?
Inhibition of JAK2/STAT3-Mediated VEGF Upregulation under High Glucose
Conditions by PEDF through a Mitochondrial ROS Pathway In Vitro
Zhi Zheng,1,2 Haibing Chen,2,3 Hui Zhao,1 Kun Liu,1 Dawei Luo,1 Yongdong
Chen,1 Yihui Chen,1 Xiaolu Yang,1 Qing Gu,1 and Xun Xu1
From the 1Department of Ophthalmology, Shanghai First People's Hospital
Affiliated Shanghai Jiao Tong University, Shanghai, China; 3Shanghai
Clinical Center for Diabetes, Shanghai Diabetes Institute, Department of
Endocrinology an |
|
n***w 发帖数: 2405 | 23 嗯。我觉得你说得对。
你们看这样写怎么样?我觉得说得是不是有点刻薄。。。
Hi, Dr. Xu,
Today I read through your paper titled "Inhibition of JAK2/STAT3-mediated
VEGF Upregulation under High Glucose Conditions by PEDF through a
Mitochondrial ROS Pathway In Vitro" which has been published in
Investigative Ophthalmology & Visual Science, January 2010.
I found the two figures from Fig 7, which are from ELISA and RT-PCR,
respectively, are exactly the same, except for the replacement of names of x
- and y- axes.
I have no offense to you t |
|
|
r*****m 发帖数: 3619 | 25 Results: 46
Select item 25597018
1.
Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated
Genes in Seminomas.
Cutcutache I, Suzuki Y, Tan IB, Ramgopal S, Zhang S, Ramnarayanan K, Gan A,
Lee HH, Tay ST, Ooi A, Ong CK, Bolthouse JT, Lane BR, Anema JG, Kahnoski RJ,
Tan P, Teh BT, Rozen SG.
Eur Urol. 2015 Jan 14. pii: S0302-2838(14)01396-7. doi: 10.1016/j.eururo.
2014.12.040. [Epub ahead of print]
PMID: 25597018 [PubMed - as supplied by publisher] Free Article
Related citations... 阅读全帖 |
|
l********n 发帖数: 260 | 26 Molecular Diagnosis & Therapy
October 2014, Volume 18, Issue 5, pp 579-585
Date: 12 Jul 2014
Development and Validation of a Tetra-Primer Amplification Refractory
Mutation System-Polymerase Chain Reaction Combined with Melting Analysis-
Assay for Clinical JAK2 V617F Mutation Detection
Weiwei Liu, Tingting Hu, Yuming Chen, Xinju Zhang, Xiaoye Gu, Ming Guan |
|
|
T****g 发帖数: 705 | 28 共同讨论, [so fun to discuss cases]
1. E
Patient has candida vaginitis, needs treatment. Typical starting with local
antifungal.
2. E
Unsatisfied wound healing is common for DM patient, especially when his
blood glucose is not very well maintain. Even thought there is no sign of
wound infection, the copious amount of fluid expressing from wound warrant a
good look at the wound. A proper drainage might help the wound healing.
3.A
This is a hard one. I had to do a little research.
Patient has thromboc... 阅读全帖 |
|
I****a 发帖数: 407 | 29 Mostly likely myeloproliferative disorder.
Recommend check bcr/abl and Jak2 mutation from blood. |
|
p***o 发帖数: 714 | 30 by pennbrook@168
好久没有正经写点东西了, 今天说说rheumatoid arthritis.
Inappropriate inflammatory cell response is associated with autoimmune
diseases, a spectrum of disorders in which the immune system malfunctions
and causes the body to attack its own organs, tissues, and cells.
The body's own immune system attacks a joint's synovial membrane, which
becomes inflamed, secretes fluid, and the cartilage becomes rough and pitted.
Rheumatoid arthritis大家应该都知道, 基本上每个药出来都是blockbuster.
现在的几种主要治疗方法是:
1. NSAID: 象Pf... 阅读全帖 |
|
b*****h 发帖数: 783 | 31 ymi 是个long term play。
它的JAK2 inhibitor-CYT387 目前看来,安全性好过INCY的。
CYT387 是个有成为blockbuster潜力的candidate
6月会update phase II data, 年底出phaseII full data.
估值参考incy。。 |
|
b*****h 发帖数: 783 | 32 JAK2 inhibitor 特效药,是这个类型的第一个新药。market 光目前这个indicator应
该800M-1B。 |
|
b*****h 发帖数: 783 | 33 INHX 是因为HCV 热,vrus 和inhx 类似的药,被10b买,大家还不急红了眼。说实话,
inhx水分已经不少了。
现在jak2要看incy到底能开发出多少市场,目前大家热情还不高。 |
|
D******9 发帖数: 2665 | 34 BTW, I studied its main drug JAK1/JAK2 inhibitor, CYT387, yesterday. Looks
very promising. |
|
W********g 发帖数: 610 | 35 税收五年一直处于增长状态...cash充足,我觉得风险相对于BPAX小一些
James S. J. Manuso
Thank you, Tim. Good afternoon, and thank you for joining us for Astex
Pharmaceuticals 2012 First Quarter Conference Call. During the quarter, we
made considerable operational progress on many fronts in discovery, research
and in the clinical and regulatory development of our drugs. Our balance
sheet remains sound and our financial performance was excellent. We ended
the quarter with $126 million in cash and marketable securities and we
po... 阅读全帖 |
|